Impact of the COVID-19 pandemic on stage at diagnosis of patients with breast cancer: An analysis of 11,752 patients from Oncoclínicas.

Authors

Cristiano Resende

Cristiano Augusto Andrade de Resende

Grupo Oncoclinicas, São Paulo, Brazil

Cristiano Augusto Andrade de Resende , Rodrigo Dienstmann , Carlos H. Barrios , Bruno Lemos Ferrari , Aline Coelho Goncalves , Fanny Cascelli , Andreza Karine Souto , Matheus Costa e Silva , Heloisa Cruz , Leandro Carvalho Oliveira , Diocesio Alves Pinto de Andrade , Eduardo Camargo Millen , Felipe Zerwes , Tomas Reinert , Paulo Moraes , Max S. Mano

Organizations

Grupo Oncoclinicas, São Paulo, Brazil, Oncoclínicas, São Paulo, Brazil, Oncocentro, Nova Lima, Brazil, Oncoclínicas, Rio De Janeiro, Brazil, Oncoclínicas, Brasília, Brazil, Fundação Pio XII, Hospital do Câncer de Barretos, Barretos, Brazil, INCA, Rio de Janeiro, Brazil, Grupo Oncoclínicas, Porto Alegre, Brazil, Centro Oncologico Antônio Ermírio de Moraes, São Paulo, Brazil

Research Funding

No funding received

Background: As a reaction to the COVID-19 pandemic, a nation-wide lockdown was enforced in Brazil in March 2020, cancer care was impacted, and cancer screening reduced. Therefore, an increase in cancer diagnoses at more advanced stages was expected. In this study, we extracted data from our nationwide real-world database to evaluate the impact of the COVID-19 pandemic on the stage at diagnosis of breast cancer (BC) cases. Methods: We explored curated electronic medical record data of female patients, over 18 years of age, diagnosed with BC and with established disease stage based on the AJCC 8th edition, who started treatment or follow-up in the Oncoclínicas (OC) between Jan 1, 2018, and Dec 31, 2021. The primary objective was to compare stage distribution at first visit during COVID-19 pandemic (2020-2021) with a historical control cohort from a period prior to the pandemic (2018-2019). We investigated stage distribution according to age at diagnosis and tumor ER/HER2 subtype in univariate models. Associations were considered significant if they had a minimum significance (P < 0.1 in Chi-square test). The historical numbers of patients with BC at OC make it possible to identify differences in the prevalence of stages in the order of 5% comparing pre and post pandemic periods with a statistical power greater than 80%. Results: We collected data for 11,752 patients with initial diagnosis of BC, with 6,492 patients belonging to the pandemic (2020-2021) and 5,260 patients to the pre-pandemic period (2018-2019). For both ER+/ HER2- and HER2+ tumors, there was a lower percentage of patients with early-stage (defined as stage I-II) in the years 2020-2021 vs 2018-2019 and a considerable increase in advanced-stage disease (defined as stage IV). For triple negative BC (TNBC), there was a significant higher percentage of patients with advanced-stage disease in the pandemic vs pre-pandemic period (table 1). Age over 50 years was associated with a greater risk of advanced stage at diagnosis after the onset of the pandemic, with an absolute increase of 7% (P two-sided <0.01) Conclusions: We observed a substantial increase in cases of advanced-stage BC in OC institutions as a result of delays in BC diagnoses due to the COVID-19 pandemic. The impact appeared greater in older adults, potentially because of stricter confinement in this group.

SUBTYPE
STAGE
2018-2019
2020-2021
P two-sided
ER+ HER2-
Stage I-II
69%
67%
0.061

Stage III
18%
18%
-

Stage IV
13%
15%
0.026
HER2+
Stage I-II
68%
58%
<0.01

Stage III
20%
22%
-

Stage IV
13%
20%
<0.01
TNBC
Stage I-II
65%
62%
0.324

Stage III
24%
21%
-

Stage IV
11%
17%
<0.01

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Etiology/Epidemiology

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10559)

DOI

10.1200/JCO.2022.40.16_suppl.10559

Abstract #

10559

Poster Bd #

435

Abstract Disclosures